Based in Bangalore, India, located in Palo Alto, CA and headquartered in Houston, Inito, a fertility-focused health technology startup, raised $29 million in Series B funding to expand its at-home diagnostics platform and develop new tests powered by AI-designed antibodies. The company has an R&D hub in Dubai.
Founded with the mission of making quantitative fertility hormone testing accessible at home, the company introduced its first fertility monitor in 2021. Unlike standard ovulation kits that track estrogen and luteinizing hormone (LH), Inito’s device also measures progesterone metabolite PdG and follicle-stimulating hormone (FSH). This broader range of hormone tracking allows users to confirm ovulation and gain deeper insights into fertility patterns.
Central to this expansion is the use of AI-engineered antibodies. Traditional antibodies, grown in animals and screened manually, are costly and limited in sensitivity. Inito’s approach treats antibodies more like software: predicting protein folding in 3D, designing synthetic antibodies virtually, and testing millions of variants before producing them in the lab. According to co-founder and CTO Varun Venkatesan, this process yields antibodies that are more sensitive, consistent, and stable than conventional methods. These advances could enable new categories of at-home tests and improve the accuracy of existing ones.
The company’s vision extends well beyond fertility. Co-founder and CEO Aayush Rai emphasizes that diagnostics should not be constrained by clinic visits or rigid lab schedules. Inito’s platform is being developed to support tests for pregnancy progression, menopause, and broader endocrine markers such as testosterone. The long-term goal is to provide individuals with the ability to measure and interpret hormonal changes across different stages of life, all from home with lab-grade confidence.
Part of the new funding will be directed toward scaling manufacturing and expanding internationally, with a focus on meeting demand in the United States and other global markets. The Series B round was led by Bertelsmann India Investments and Fireside Ventures, bringing Inito’s total funding to approximately $45 million. Previous backers include Y Combinator, former Nurx CEO Varsha Rao, and several physicians and family offices.
Last updated: December 26th, 2025
